Jeffrey W. Tyner, Ph.D. - Publications

Affiliations: 
Oregon Health and Science University, Portland, OR 
Area:
Cell Biology, Microbiology Biology, Molecular Biology, Public Health

121 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Tyner JW, Bottomly D, Wilmot B, McWeeney S. What do functional genomics tell us about pathogenesis of AML? Best Practice & Research. Clinical Haematology. 32: 101101. PMID 31779979 DOI: 10.1016/j.beha.2019.101101  0.4
2019 Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, et al. Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances. 3: 3201-3213. PMID 31698451 DOI: 10.1182/bloodadvances.2019000641  0.44
2019 Choonoo G, Blucher AS, Higgins S, Boardman M, Jeng S, Zheng C, Jacobs J, Anderson A, Chamberlin S, Evans N, Vigoda M, Cordier B, Tyner JW, Kulesz-Martin M, McWeeney SK, et al. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. Plos One. 14: e0223639. PMID 31596908 DOI: 10.1371/journal.pone.0223639  0.4
2019 Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, ... ... Tyner JW, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. PMID 31543464 DOI: 10.1016/j.ccell.2019.08.004  0.44
2019 Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, ... ... Tyner JW, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/blood.2019000611  0.44
2019 Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, ... Tyner JW, et al. The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells. Cancer Discovery. PMID 31048320 DOI: 10.1158/2159-8290.CD-19-0125  0.44
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30924767 DOI: 10.7554/eLife.47174  0.44
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/eLife.40033  0.44
2019 Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, ... ... Tyner JW, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications. 10: 244. PMID 30651561 DOI: 10.1038/s41467-018-08263-x  0.44
2019 Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR. Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research. PMID 30642575 DOI: 10.1016/j.leukres.2018.11.010  0.44
2018 Edwards DK, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, ... ... Tyner JW, et al. CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. PMID 30425048 DOI: 10.1182/blood-2018-03-838946  0.4
2018 Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/s41586-018-0623-z  0.44
2018 Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. Science Signaling. 11. PMID 30018082 DOI: 10.1126/scisignal.aao5617  0.44
2018 Guo X, Zhang Y, Mayakonda A, Madan V, Ding LW, Lin LH, Zia S, Gery S, Tyner JW, Zhou W, Yin D, Lin DC, Koeffler HP. ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer. Oncogene. PMID 29980791 DOI: 10.1038/s41388-018-0371-4  0.6
2018 Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 9: 24576-24589. PMID 29872489 DOI: 10.18632/oncotarget.25191  0.44
2018 Ouyang X, Barling A, Lesch A, Tyner JW, Choonoo G, Zheng C, Jeng S, West TM, Clayburgh D, Courtneidge SA, McWeeney SK, Kulesz-Martin M. Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. Cancer Biology & Therapy. 1-37. PMID 29856687 DOI: 10.1080/15384047.2018.1451285  0.4
2018 Chow M, Gao L, MacManiman JD, Bicocca VT, Chang BH, Alumkal JJ, Tyner JW. Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. Oncogene. PMID 29849118 DOI: 10.1038/s41388-018-0299-8  0.44
2018 Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. The Journal of Biological Chemistry. PMID 29572350 DOI: 10.1074/jbc.RA118.002417  0.44
2018 Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK. Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia. Haematologica. PMID 29567769 DOI: 10.3324/haematol.2018.190926  0.44
2017 Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill PS. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644. PMID 29296810 DOI: 10.1182/bloodadvances.2017005694  0.44
2017 Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, et al. A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. PMID 29284681 DOI: 10.3324/haematol.2017.165282  0.44
2017 Kanojia D, Garg M, Martinez J, M T A, Luty SB, Doan NB, Said JW, Forscher C, Tyner JW, Koeffler HP. Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. Journal of Hematology & Oncology. 10: 173. PMID 29132397 DOI: 10.1186/s13045-017-0540-x  0.44
2017 Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, ... ... Tyner JW, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. PMID 28784769 DOI: 10.1073/pnas.1703094114  0.44
2017 Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, Wilmot B, McWeeney SK, Kükenshöner T, Hantschel O, Tyner JW. Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function. Cancer Research. PMID 28652245 DOI: 10.1158/0008-5472.CAN-17-1052  0.4
2017 Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Reports. 18: 3204-3218. PMID 28355571 DOI: 10.1016/j.celrep.2017.03.018  0.44
2017 Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, ... Tyner JW, et al. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. PMID 28186983 DOI: 10.18632/oncotarget.15146  0.44
2017 Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, ... ... Tyner JW, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug resistant ALL. Blood. PMID 28122742 DOI: 10.1182/blood-2016-09-738070  0.4
2016 Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia. Blood. PMID 28028025 DOI: 10.1182/blood-2016-10-695981  0.44
2016 Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leukemia Research. 53: 39-49. PMID 28013106 DOI: 10.1016/j.leukres.2016.12.002  0.4
2016 Richard NP, Pippa R, Cleary MM, Puri A, Tibbitts D, Mahmood S, Christensen DJ, Jeng S, McWeeney S, Thomas Look A, Chang BH, Tyner JW, Vitek MP, Odero MD, Sears R, et al. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget. PMID 27705940 DOI: 10.18632/oncotarget.12394  0.4
2016 Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Research. PMID 27671675 DOI: 10.1158/0008-5472.CAN-15-3569  0.44
2016 Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Science Translational Medicine. 8: 354ra114. PMID 27582059 DOI: 10.1126/scitranslmed.aaf5309  0.6
2016 Agarwal A, Tyner JW. RNAi Screening of Leukemia Cells Using Electroporation. Methods in Molecular Biology (Clifton, N.J.). 1470: 85-94. PMID 27581286 DOI: 10.1007/978-1-4939-6337-9_7  0.6
2016 Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Scientific Reports. 6: 28163. PMID 27320899 DOI: 10.1038/srep28163  0.6
2016 Tyner JW. JAKed up phenotype of CEBPA-mutant AML. Blood. 127: 2946-7. PMID 27313323 DOI: 10.1182/blood-2016-04-709535  0.6
2016 Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, Baloglu E, Kanojia D, Shang L, Xu X, Yang H, ... Tyner JW, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. PMID 27196599 DOI: 10.1136/gutjnl-2016-311818  0.6
2016 Watanabe-Smith K, Tognon C, Tyner JW, Meijerink JP, Druker BJ, Agarwal A. Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia. Leukemia. PMID 27118405 DOI: 10.1038/leu.2016.95  0.6
2015 Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. CurēUs. 7: e414. PMID 26870618 DOI: 10.7759/cureus.414  0.44
2015 Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, ... ... Tyner JW, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. PMID 26677978 DOI: 10.1158/0008-5472.CAN-15-0817  0.6
2015 Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. PMID 26648538 DOI: 10.1038/leu.2015.337  0.44
2015 Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, M T A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, ... ... Tyner JW, et al. Genomic landscape of liposarcoma. Oncotarget. PMID 26643872 DOI: 10.18632/oncotarget.6464  0.6
2015 Dao KH, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2015: 264-71. PMID 26637732 DOI: 10.1182/asheducation-2015.1.264  0.32
2015 Lue HW, Cole B, Rao SA, Podalak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. PMID 26625308 DOI: 10.18632/oncotarget.5971  0.6
2015 Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. American Journal of Hematology. PMID 26573090 DOI: 10.1002/ajh.24245  0.6
2015 Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide CA, Loriaux MM, Stevens EA, Tyner JW. The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26475333 DOI: 10.1158/1078-0432.CCR-14-3100  0.6
2015 Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget. PMID 26254279  0.6
2015 Viola S, Traer E, Huan J, Hornick NI, Tyner JW, Agarwal A, Loriaux M, Johnstone B, Kurre P. Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance. British Journal of Haematology. PMID 26095727 DOI: 10.1111/bjh.13551  0.6
2015 Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75: 2146-50. PMID 26032424 DOI: 10.1158/0008-5472.CAN-14-1576  0.6
2015 Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nature Cell Biology. 17: 665-77. PMID 25915125 DOI: 10.1038/ncb3158  0.6
2015 Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8: 39. PMID 25895498 DOI: 10.1186/s13045-015-0132-6  0.6
2015 Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Tyner JW, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/j.ccell.2015.02.003  0.6
2015 Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA, Tan SZ, Tokatly I, Zaiden N, Poellinger L, Mori S, Yang H, Tyner JW, Koeffler HP. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Molecular Oncology. 9: 889-905. PMID 25637283 DOI: 10.1016/j.molonc.2015.01.002  0.6
2015 Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, ... ... Tyner JW, et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature Medicine. 21: 71-5. PMID 25485910 DOI: 10.1038/nm.3751  0.6
2015 Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75: 880-91. PMID 25432174 DOI: 10.1158/0008-5472.CAN-14-0573  0.6
2015 Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. Oncogene. 34: 2991-9. PMID 25109334 DOI: 10.1038/onc.2014.243  0.6
2014 Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 3: 67-9. PMID 25180155 DOI: 10.1016/j.lrr.2014.07.002  0.6
2014 Tyner JW. Functional genomics for personalized cancer therapy. Science Translational Medicine. 6: 243fs26. PMID 24990879 DOI: 10.1126/scitranslmed.3009586  0.6
2014 Kim MS, Zhong Y, Yachida S, Rajeshkumar NV, Abel ML, Marimuthu A, Mudgal K, Hruban RH, Poling JS, Tyner JW, Maitra A, Iacobuzio-Donahue CA, Pandey A. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Molecular & Cellular Proteomics : McP. 13: 2803-11. PMID 24895378 DOI: 10.1074/mcp.M114.038547  0.6
2014 Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 6383-8. PMID 24733895 DOI: 10.1073/pnas.1403608111  0.6
2014 Yao H, Goldman DC, Nechiporuk T, Kawane S, McWeeney SK, Tyner JW, Fan G, Kerenyi MA, Orkin SH, Fleming WH, Mandel G. Corepressor Rcor1 is essential for murine erythropoiesis. Blood. 123: 3175-84. PMID 24652990 DOI: 10.1182/blood-2013-11-538678  0.6
2014 Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Al Masri A, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia. 28: 1978-87. PMID 24637335 DOI: 10.1038/leu.2014.109  0.6
2014 Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A. TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database : the Journal of Biological Databases and Curation. 2014: bau007. PMID 24573880 DOI: 10.1093/database/bau007  0.6
2014 Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2092-103. PMID 24436473 DOI: 10.1158/1078-0432.CCR-13-2575  0.6
2014 Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 123: 1516-24. PMID 24408322 DOI: 10.1182/blood-2013-07-518381  0.6
2014 Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. The Journal of Biological Chemistry. 289: 5820-7. PMID 24403076 DOI: 10.1074/jbc.M113.508440  0.6
2013 Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood. 122: 3705-6. PMID 24288407 DOI: 10.1182/blood-2013-10-531665  0.6
2013 Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B. Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. Genome Medicine. 5: 103. PMID 24286512 DOI: 10.1186/gm509  0.6
2013 Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 110: 19519-24. PMID 24218589 DOI: 10.1073/pnas.1319583110  0.6
2013 Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 122: 3628-31. PMID 24081659 DOI: 10.1182/blood-2013-06-509976  0.6
2013 Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma. Molecular Cancer Research : McR. 11: 1303-13. PMID 23928059 DOI: 10.1158/1541-7786.MCR-12-0598  0.6
2013 Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway Leukemia. 27: 2094-2096. PMID 23900138 DOI: 10.1038/leu.2013.228  0.6
2013 Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 122: 1707-11. PMID 23896413 DOI: 10.1182/blood-2013-05-500959  0.6
2013 Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. Journal of Cancer Research and Clinical Oncology. 139: 1507-14. PMID 23824064 DOI: 10.1007/s00432-013-1465-6  0.6
2013 Dao KH, Rotelli MD, Brown BR, Yates JE, Rantala J, Tognon C, Tyner JW, Druker BJ, Bagby GC. The PI3K/Akt1 pathway enhances steady-state levels of FANCL. Molecular Biology of the Cell. 24: 2582-92. PMID 23783032 DOI: 10.1091/mbc.E13-03-0144  0.6
2013 Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, ... ... Tyner JW, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. The New England Journal of Medicine. 368: 1781-90. PMID 23656643 DOI: 10.1056/NEJMoa1214514  0.6
2013 Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 27: 1870-3. PMID 23604229 DOI: 10.1038/leu.2013.122  0.6
2013 O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, ... Tyner JW, et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Research. 73: 3356-70. PMID 23576564 DOI: 10.1158/0008-5472.CAN-12-3904  0.6
2013 Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Translational Oncology. 6: 158-68. PMID 23544168 DOI: 10.1593/tlo.12307  0.6
2013 Davis LE, Hofmann NE, Li G, Huang ET, Loriaux MM, Bracha S, Helfand SC, Mata JE, Marley K, Mansoor A, Tyner JW, Abraham J, Séguin B, Keller C. A case study of personalized therapy for osteosarcoma. Pediatric Blood & Cancer. 60: 1313-9. PMID 23526721 DOI: 10.1002/pbc.24512  0.6
2013 Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discovery. 3: 564-77. PMID 23471820 DOI: 10.1158/2159-8290.CD-12-0504  0.6
2013 Dao KH, Tyner JW. Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1309-11. PMID 23382113 DOI: 10.1158/1078-0432.CCR-12-3934  0.6
2013 Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK. HitWalker: variant prioritization for personalized functional cancer genomics. Bioinformatics (Oxford, England). 29: 509-10. PMID 23303510 DOI: 10.1093/bioinformatics/btt003  0.6
2013 Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. The Journal of Pharmacology and Experimental Therapeutics. 344: 378-87. PMID 23220742 DOI: 10.1124/jpet.112.200832  0.6
2013 Kulesz-Martin M, Lagowski J, Olson S, Wortham A, West T, Thomas G, Ryan CW, Tyner JW. A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma Cancer Biology and Therapy. 14: 95-99. PMID 23192268 DOI: 10.4161/cbt.22960  0.6
2013 Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Research. 73: 285-96. PMID 23087056 DOI: 10.1158/0008-5472.CAN-12-1906  0.6
2012 Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 22: 656-67. PMID 23153538 DOI: 10.1016/j.ccr.2012.08.027  0.6
2012 Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 426: 363-8. PMID 22960170 DOI: 10.1016/j.bbrc.2012.08.092  0.6
2012 Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, Ngan BD, Braunstein GD, Koeffler HP. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncology Letters. 3: 807-815. PMID 22740998 DOI: 10.3892/ol.2012.579  0.6
2012 Fleischman AG, Tyner JW. JAK2 V617F down-modulates MPL. Blood. 119: 4579-80. PMID 22596167 DOI: 10.1182/blood-2012-03-417261  0.6
2012 Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A, Neff TL, Tyner JW, Dunlap J, Corless CL, Fan G. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia. 26: 2144-6. PMID 22425895 DOI: 10.1038/leu.2012.74  0.6
2012 Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, ... ... Tyner JW, et al. TSLP signaling network revealed by SILAC-based phosphoproteomics. Molecular & Cellular Proteomics : McP. 11: M112.017764. PMID 22345495 DOI: 10.1074/mcp.M112.017764  0.6
2012 Anur P, Yates J, Garbati MR, Vanderwerf S, Keeble W, Rathbun K, Hays LE, Tyner JW, Svahn J, Cappelli E, Dufour C, Bagby GC. p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes. Blood. 119: 1992-2002. PMID 22234699 DOI: 10.1182/blood-2011-06-354647  0.6
2012 Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatric Blood & Cancer. 59: 576-9. PMID 22038978 DOI: 10.1002/pbc.23383  0.6
2012 Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia. 26: 623-32. PMID 21960246 DOI: 10.1038/leu.2011.249  0.6
2011 Tyner JW. Phosphoproteomics microarray screen reveals novel interaction between MPL and Tensin2: implications for biology, disease and therapeutics. Cell Cycle (Georgetown, Tex.). 10: 2621-2. PMID 21829102 DOI: 10.4161/cc.10.16.16391  0.6
2011 Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.CAN-10-3224  0.6
2011 Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular Cancer Therapeutics. 10: 1028-35. PMID 21482694 DOI: 10.1158/1535-7163.MCT-10-1044  0.6
2011 Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117: 591-4. PMID 20959606 DOI: 10.1182/blood-2010-03-275305  0.6
2010 Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Research. 70: 6233-7. PMID 20670955 DOI: 10.1158/0008-5472.CAN-10-0429  0.6
2010 Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115: 5232-40. PMID 20385788 DOI: 10.1182/blood-2009-05-223727  0.6
2010 Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia. 24: 226-9. PMID 19759561 DOI: 10.1038/leu.2009.196  0.6
2009 O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16: 401-12. PMID 19878872 DOI: 10.1016/j.ccr.2009.09.028  0.6
2009 Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences of the United States of America. 106: 8695-700. PMID 19433805 DOI: 10.1073/pnas.0903233106  0.6
2009 Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, O'Hare T, Deininger MW, Druker BJ, Loriaux MM. Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia. 23: 1345-8. PMID 19340004 DOI: 10.1038/leu.2009.66  0.6
2009 Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 113: 1749-55. PMID 19075190 DOI: 10.1182/blood-2008-04-152157  0.6
2009 Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia. 23: 406-9. PMID 18615102 DOI: 10.1038/leu.2008.187  0.6
2008 Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. Plos One. 3: e3593. PMID 18974832 DOI: 10.1371/journal.pone.0003593  0.6
2008 Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD, Castro M, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nature Medicine. 14: 633-40. PMID 18488036 DOI: 10.1038/nm1770  0.6
2008 O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proceedings of the National Academy of Sciences of the United States of America. 105: 5507-12. PMID 18367669 DOI: 10.1073/pnas.0800587105  0.6
2008 Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/blood-2007-07-101394  0.6
2008 Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 111: 2238-45. PMID 18025156 DOI: 10.1182/blood-2007-06-097253  0.6
2007 Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 110: 323-33. PMID 17360941 DOI: 10.1182/blood-2006-10-052282  0.6
2006 Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 20: 2008-14. PMID 16990784 DOI: 10.1038/sj.leu.2404374  0.6
2006 Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/j.ccr.2006.06.002  0.6
2006 Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, Battaile JT, Patel AC, Patterson GA, Castro M, Spoor MS, You Y, Brody SL, Holtzman MJ. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. The Journal of Clinical Investigation. 116: 309-21. PMID 16453019 DOI: 10.1172/JCI25167  0.6
2005 Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature Medicine. 11: 1180-7. PMID 16208318 DOI: 10.1038/nm1303  0.6
2005 Holtzman MJ, Tyner JW, Kim EY, Lo MS, Patel AC, Shornick LP, Agapov E, Zhang Y. Acute and chronic airway responses to viral infection: implications for asthma and chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2: 132-40. PMID 16113481 DOI: 10.1513/pats.200502-015AW  0.6
2005 Holtzman MJ, Kim EY, Lo MS, Tyner JW, Shornick LP, Sumino KC, Zhang Y. Defining and adjusting divergent host responses to viral infection. Immunologic Research. 32: 123-41. PMID 16106064 DOI: 10.1385/IR:32:1-3:123  0.6
2004 Holtzman MJ, Shornick LP, Grayson MH, Kim EY, Tyner JW, Patel AC, Agapov E, Zhang Y. "Hit-and-run" effects of paramyxoviruses as a basis for chronic respiratory disease. The Pediatric Infectious Disease Journal. 23: S235-45. PMID 15577579 DOI: 10.1097/01.inf.0000144674.24802.c1  0.6
2003 O'Sullivan MP, Tyner JW, Holtzman MJ. Apoptosis in the airways: another balancing act in the epithelial program. American Journal of Respiratory Cell and Molecular Biology. 29: 3-7. PMID 12821445 DOI: 10.1165/rcmb.F273  0.6
2002 Holtzman MJ, Morton JD, Shornick LP, Tyner JW, O'Sullivan MP, Antao A, Lo M, Castro M, Walter MJ. Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. Physiological Reviews. 82: 19-46. PMID 11773608 DOI: 10.1152/physrev.00020.2001  0.6
Show low-probability matches.